This page uses content from Wikipedia and is licensed under CC BY-SA.

SDB-005

SDB-005
SDB-005 structure.png
Legal status
Legal status
Identifiers
ChemSpider
Chemical and physical data
FormulaC23H22N2O2
Molar mass358.441 g·mol−1
3D model (JSmol)

SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

The code number SDB-005 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).[2]

Original, non designer drug SDB-005

However, SDB-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in Europe as a designer drug, and was entered into the EMCDDA synthetic drug database under this name.[3] Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.

See also

References

  1. ^ "SDB-005". Cayman Chemical. Retrieved 27 June 2015.
  2. ^ "The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse". ACS Chemical Neuroscience. 4 (7): 1081–1092. July 2013. doi:10.1021/cn400035r. PMC 3715837. PMID 23551277.
  3. ^ EWS_EU: Neue Psychoaktive Substanzen, April 2015